Compare Adaptive Biotechnologies Corp (ADPT) vs A O Smith Corp (AOS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs A O Smith Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while A O Smith Corp trades at $59.69 (market cap $8.45B). The key difference: A O Smith Corp is far larger — about 2.5× Adaptive Biotechnologies Corp's market cap, and A O Smith Corp pays a 2.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AOS | |
|---|---|---|
Market Cap | $3.33B | $8.45B |
Sector | Health | Industrials |
52-Week High | $22.37 | $80.47 |
52-Week Low | $10.24 | $55.78 |
Enterprise Value | $3.19B | $8.90B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
A.O. Smith (AOS) trades at $61.31, down 2.25% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported a Q1 2026 earnings miss ($0.85 actual vs. $0.94 expected) but maintains strong profitability with a 13.84% net margin and 28.27% ROE. Recent leadership changes include CEO Stephen Shafer becoming chairman as of July 1, 2026 (PRNewswire, June 22, 2026).
The stock shows mixed signals: solid fundamentals and a $68 consensus price target suggest upside, but recent earnings weakness and repeated Zacks Strong Sell ratings (June 18, 2026) indicate near-term headwinds. Investors face risks from China market softness and competitive pressures, though cash flow stability and dividend payments provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →
